

## Laboratory Group Limbach expands lipid analysis with numares test

**Regensburg, 06 July 2016 - The Laboratory Group Limbach is using the in vitro diagnostic (IVD) test *LipoComplete* from numares. Meaning Limbach's lipid analysis service portfolio now includes a mass-market blood test for determining individual lipoprotein profiles. In addition to the standard lipid metabolism parameters (triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol), *LipoComplete* provides further information on the particle properties (concentration, mean diameter) of various lipoprotein subclasses, such as the highly atherogenic small dense LDL (sdLDL). The new test is designed to allow a more differentiated risk assessment of cardiovascular diseases.**

By adding the *LipoComplete* test to its service portfolio, Limbach has expanded its lipoprotein diagnostics to include a modern and high-throughput routine analysis. The test is based on the CE-marked IVD test *lipoFIT-S100*, which numares launched in 2015. It allows 29 lipoprotein parameters such as particle concentration and diameter to be determined as well as the lipid concentration of lipoprotein particles such as triglycerides and cholesterol. Limbach wants to establish the new test as part of routine diagnostics and use it for things such as risk stratification and treatment monitoring during statin therapy. However, LipoDens® will continue to be the reference method of lipoprotein analytics, especially for the examination of problematic samples.

Limbach is already offering the product LipoDens® for advanced lipoprotein diagnostics. The analysis of lipoprotein subclasses with LipoDens® is performed by way of ultracentrifugation, a precise method that can be used for problematic sera in particular. However, particle properties such as concentration and the average diameter of lipoprotein particles cannot be determined with the LipoDens® method. Ultracentrifugation is also a very complicated method with limited sample throughput.

"Our goal is to offer a differentiated analysis for each patient. And we now have the right procedure to do so thanks to the high-throughput solution from numares. We can now supply the parameters most important for physicians' diagnosis and therapy - accurately and in the shortest possible time," says Dr. Dietmar Plonné, dyslipidemia expert at the Limbach laboratory group.

“Until now, lipoprotein analyses were limited to 16 tests per day using the gold standard LipoDens® and as such were not suitable for high demand,” adds Dr. Volker Pfahlert, chairman of the Executive Board at numares AG. “With *LipoComplete*, Limbach has expanded its test portfolio to include an analysis method that enables a throughput of more than 250 samples per day.”

*LipoComplete* is now available to any patient in Germany. The blood test can be requested via your family doctor and ordered at the MVZ Laboratory Ravensburg of Limbach Group.

### **Background:**

The measurement of lipids in the blood is an integral part of today’s diagnostic routine. As part of basic diagnostic screening for widespread dyslipidemia and CHD risk stratification, triglycerides, total cholesterol, LDL<sup>1</sup> cholesterol and HDL<sup>2</sup> cholesterol are determined in serum as standard. These are of a varying composition, packed in so-called lipoprotein classes that are divided into further subclasses according to size, density and particle concentrations, and that differ in their atherogenic effect. A growing number of scientific publications and guidelines show that considering lipoprotein subclasses and particle concentrations such as LDL-P can contribute to a better risk stratification and prediction of cardiovascular events.

<sup>1</sup>LDL = low density lipoprotein, <sup>2</sup>HDL = high density lipoprotein

### **About numares**

**numares** is a specialized developer and provider of analytic and diagnostic test systems based on nuclear magnetic resonance (NMR) spectroscopy and numares’ proprietary Magnetic Group Signaling (MGS) technology.

**numares HEALTH** develops and markets in-vitro diagnostic tests with the CE marking and integrated test systems for high-throughput use in clinical diagnostics and life science research. The highly standardized tests provide valuable information on the disease status of patients in the indication areas of cardiovascular diseases, nephrology and oncology.

In addition, **numares HEALTH** provides its test systems to the pharmaceutical industry on a fee-for-service basis. They can be used for example to investigate the therapeutic effects of drugs as part of clinical trials. The company also supports customers with complex issues and clinical trials, drawing on its many years of expertise and experience in the area of NMR spectroscopy and metabolomics.

[www.numares.com](http://www.numares.com)

### **About Limbach**

The Medical Care Center Ravensburg - also known as Dr. Gärtner laboratory - belongs to the Limbach Group and stands for quality-conscious medical laboratory diagnostics in Germany. With a total of 30 individual laboratories under medical direction, the newly created Limbach Group is a reliable partner for physicians, hospitals and other medical facilities. The diagnostics services offered throughout Germany include both basic diagnostics and special analytics as well as medical advice for all clinical disciplines.

### **Contact details Limbach:**

PD Dr. med. Dietmar Plonné  
Facharzt für Laboratoriumsmedizin  
Tel.: +49 731-85070540  
Fax: +49 731-85070568  
E-Mail: [d.plonne@mvz-labor-ulm.de](mailto:d.plonne@mvz-labor-ulm.de)

### **For further information please contact:**

numares AG  
Dipl.-Biol. Christiane Proll, MBA  
Tel.: +49 941 2809 49-14  
E-Mail: [christiane.proll@numares-health.com](mailto:christiane.proll@numares-health.com)

IRA WÜLFING KOMMUNIKATION GmbH  
Dr. Reinhard Saller  
Tel.: +49 89 2000 30-38  
E-Mail: [reinhard.saller@wuefing-kommunikation.de](mailto:reinhard.saller@wuefing-kommunikation.de)